Interpace Biosciences (IDXG)
(Delayed Data from OTC)
$1.57 USD
+0.12 (8.08%)
Updated Sep 6, 2024 02:01 PM ET
NA Value
NA Growth NA Momentum NA VGMBrokerage Reports
0 items in cart
Interpace Biosciences, Inc. [IDXG]
Reports for Purchase
Showing records 1 - 20 ( 63 total )
Company: Interpace Biosciences, Inc.
Industry: Medical Services
Company: Interpace Biosciences, Inc.
Industry: Medical Services
1Q22 Financial Results Reported; Reiterate Neutral
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Company: Interpace Biosciences, Inc.
Industry: Medical Services
2021 Financial Results Reported; Reiterate Neutral
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Company: Interpace Biosciences, Inc.
Industry: Medical Services
3Q21 Financial Results Reported; Downgrade to Neutral
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Company: Interpace Biosciences, Inc.
Industry: Medical Services
Company: Interpace Biosciences, Inc.
Industry: Medical Services
Company: Interpace Biosciences, Inc.
Industry: Medical Services
Solid Financial Performance in 1Q21; Reiterate Buy; Raising PT to $11
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Company: Interpace Biosciences, Inc.
Industry: Medical Services
Revenue Beat With EBITDA Break-Even in Sight; 2020 Financials; Raising PT to $9
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Company: Interpace Biosciences, Inc.
Industry: Medical Services
New Pancreatic Cysts Risk Assessment Biomarker In-Licensed; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Company: Interpace Biosciences, Inc.
Industry: Medical Services
3Q20 Financial Results Reported; Reiterate Buy; Lowering PT to $6
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Company: Interpace Biosciences, Inc.
Industry: Medical Services
Thyroid Assays Clinical Validation Published; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Company: Interpace Biosciences, Inc.
Industry: Medical Services
2Q20 Financial Results Reported; Reiterate Buy; Modulating PT to $10
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Company: Interpace Biosciences, Inc.
Industry: Medical Services
1Q20 Financial Results Reported; Reiterate Buy; Modulating PT to $11
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Company: Interpace Biosciences, Inc.
Industry: Medical Services
2019 Financial Results Reported; Reiterate Buy; Lowering PT to $12
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Company: Interpace Biosciences, Inc.
Industry: Medical Services
New In-Network Contract in Massachusetts; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Company: Interpace Biosciences, Inc.
Industry: Medical Services
ThyGeNEXT with ThyraMIR Clinical Data Accepted for Publication; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Company: Interpace Biosciences, Inc.
Industry: Medical Services
Company: Interpace Biosciences, Inc.
Industry: Medical Services
ThyraMIR Medicare Reimbursement Raised; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Company: Interpace Biosciences, Inc.
Industry: Medical Services
$20M Financing Completed; Reverse Split Effected; Reiterate Buy; Adjusting PT to $15
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Company: Interpace Biosciences, Inc.
Industry: Medical Services
New BarreGEN Study Expands Target Population; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y